Correlation Between Karyopharm Therapeutics and Histogen
Can any of the company-specific risk be diversified away by investing in both Karyopharm Therapeutics and Histogen at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Karyopharm Therapeutics and Histogen into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Karyopharm Therapeutics and Histogen, you can compare the effects of market volatilities on Karyopharm Therapeutics and Histogen and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Karyopharm Therapeutics with a short position of Histogen. Check out your portfolio center. Please also check ongoing floating volatility patterns of Karyopharm Therapeutics and Histogen.
Diversification Opportunities for Karyopharm Therapeutics and Histogen
0.46 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Karyopharm and Histogen is 0.46. Overlapping area represents the amount of risk that can be diversified away by holding Karyopharm Therapeutics and Histogen in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Histogen and Karyopharm Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Karyopharm Therapeutics are associated (or correlated) with Histogen. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Histogen has no effect on the direction of Karyopharm Therapeutics i.e., Karyopharm Therapeutics and Histogen go up and down completely randomly.
Pair Corralation between Karyopharm Therapeutics and Histogen
Given the investment horizon of 90 days Karyopharm Therapeutics is expected to under-perform the Histogen. But the stock apears to be less risky and, when comparing its historical volatility, Karyopharm Therapeutics is 3.72 times less risky than Histogen. The stock trades about -0.65 of its potential returns per unit of risk. The Histogen is currently generating about 0.21 of returns per unit of risk over similar time horizon. If you would invest 2.00 in Histogen on September 25, 2024 and sell it today you would earn a total of 0.77 from holding Histogen or generate 38.25% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Karyopharm Therapeutics vs. Histogen
Performance |
Timeline |
Karyopharm Therapeutics |
Histogen |
Karyopharm Therapeutics and Histogen Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Karyopharm Therapeutics and Histogen
The main advantage of trading using opposite Karyopharm Therapeutics and Histogen positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Karyopharm Therapeutics position performs unexpectedly, Histogen can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Histogen will offset losses from the drop in Histogen's long position.Karyopharm Therapeutics vs. X4 Pharmaceuticals | Karyopharm Therapeutics vs. Hookipa Pharma | Karyopharm Therapeutics vs. Mereo BioPharma Group | Karyopharm Therapeutics vs. Acumen Pharmaceuticals |
Histogen vs. Fate Therapeutics | Histogen vs. Caribou Biosciences | Histogen vs. Karyopharm Therapeutics | Histogen vs. X4 Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Complementary Tools
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |